More recently, novel formulations of double and triple gut hormone receptor agonists (involving glucose-dependent insulinotropic polypeptide [GIP] and glucagon) have been successfully developed [4], and other hormones, such as oestrogens and thyroid hormones, have also shown potential for use as therapies for the treatment of diabetes. This evidence concerns the gene GIP and diabetes mellitus.